Related Experiment Video

Updated: Jul 8, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions

Olivia Aranha1, Mark Agulnik

  • 1Northwestern University, Robert H Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Chicago, Illinois 60611, USA.

Expert Opinion on Therapeutic Targets
|January 23, 2008
PubMed
Abstract

Insights

Investigational new drugs targeting soft tissue sarcomas show promise for patients with advanced disease. Ongoing clinical trials explore novel molecular targets to improve outcomes for these rare cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Soft tissue sarcomas are rare cancers with significant chemotherapy resistance.
  • Metastatic and progressive disease necessitates novel therapeutic strategies.
  • Investigational new drugs offer hope for patients with limited treatment options.

Purpose of the Study:

  • To review molecular mechanisms driving soft tissue sarcoma development.
  • To discuss targeted therapies aimed at improving patient outcomes.
  • To highlight the potential of molecularly targeted treatments for rare tumors.

Main Methods:

  • Comprehensive literature search using Medline and American Society of Clinical Oncology databases.
  • Keyword: 'soft tissue sarcoma'.
  • Inclusion criteria focused on studies utilizing targeted therapies in soft tissue sarcoma treatment.

Main Results:

  • Ongoing Phase II clinical trials are evaluating novel therapeutic targets.
  • Established molecular targets are also being investigated in new treatment paradigms.
  • The landscape of soft tissue sarcoma treatment is evolving with targeted approaches.

Conclusions:

  • Targeted therapies represent a promising avenue for managing soft tissue sarcomas.
  • Further clinical trials are crucial for validating new molecular targets.
  • Advancements in understanding molecular mechanisms are paving the way for improved patient care.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...